Associate Professor Qihan Dong

PhD
Honorary Associate Professor
Department of Endocrinology, Central Clinical School, Faculty of Medicine and Health

Member of the Charles Perkins Centre

Telephone +61 2 86271714

Map

Biographical details

Associate Professor Dong was trained as a Physician but pursued a full time research career after being awarded PhD in 1992 from The University of Sydney. He then continued as a Fogarty Fellow at the National Institutes of Health, USA. On returning to Sydney in 1996, he was appointed as the Head of the Cancer Biology Group. Dong was awarded one of the 12 inaugural Career Development & Support NSW Cancer Institute Fellowships in 2005. He has been the Director of anti-cancer Chinese Medicine evaluation programe establisehd in 2016. He has published 73 papers (total citations of 3,028), with an average Impact factor of 4.1. He is the first or senior/corresponding author on 70% of them.

Research interests

In a multicenter study, he was involved in cloning the gene for multiple endocrine neoplasia type 1 (MEN-1), which was published in the Science. He also cloned the gene encoding the α-subunit of the G protein. His research team first proposed an increase in phospholipase A2 gene expression and activity but a decrease in native phospholipase A2 inhibitor gene expression in prostate cancer. The content has been included in the second edition of "Encyclopedia of Cancer." His phospholipase A2 inhibitor treatment of prostate cancer has entered the international patent approval phase.

Currently, his team has established a platform to model quiescent tumour cells and cell cycle re-entry. Various drugs, including traditional Chinese medicine active ingredients, are tested on the platform to determine if they can prevent quiescent tumour cells from re-entering cell cycle, as this is a mechanism for tumour progression and recurrence.

Professor Dong's work also attracted the attention in China. In November 2016 and 2017, the World Federation of Chinese Medicine held Australia-China Forum on globalization of traditional Chinese medicine in Sydney. Professor Dong co-chaired the meeting and made a keynote speech. He is Adjunct Professor of Shanghai University of Traditional Chinese Medicine and affiliated Yue-Yang Hospital.

Teaching and supervision

Dong has taken 16 students (10 PhD and 6 Master) since his appointment as Group leader in 1996. Ten of them have completed and now work in biomedical field. Dong also takes responsibility to teach Senior Registrar from Royal Prince Alfred Hospital. Two Gordon Craig Fellows have spent one year (full time) in Dong’s laboratory to conduct basic research on prostate cancer. He is the overseas supervisor for Chinese students sponsored by National China Scholar Council (6 have completed their studies and returned to China).

Current projects

Dong's team is investigating the mechanism of, and the way to prevent, cancer recurrence. Cancers are made up of both actively dividing and "resting" cancer cells. These “resting” (quiescent) cancer cells are thought to be central to recurrence, after actively dividing cancer cells are eliminated by chemo- or radio-therapy. This is important as the regulatory signals required for quiescent cancer cells to re-enter the cell cycle have not been fully elucidated. Identification of these signals will provide needed molecular targets for preventing cancer recurrence. In addition, the team has made progress in designing prevention strategies with the ultimate goal of providing cancer survivors with these interventions when the disease is in remission. Based on the principal of efficacy and no toxicity, the team has determined the potential of compounds isolated from edible plant and herbal medicine in blocking the transition from the quiescent to actively dividing state of cancer cells, or sensitising cancer cells to radiation therapy.

In the media

Selected grants

2014

  • CLARIOstar Multifunctional Microplate Reader for Shared Used at the Open Access, Multi-User Molecular Biology Core Facility; Huang M, Scolyer R, Fraser S, Sahni S, Speranza T, Owens T, Barrs V, Ju Y, Kovacevic Z, Lu Z, Camp A, Slobedman B, Morris B, Oliver B, Dos Remedios C, Kalinowski D, Fu D, Lai D, Lovicu F, Allbutt H, Triccas J, Burgess J, Kril J, Dixon K, Rendina L, Byrne M, King N, Groundwater P, Williamson P, Ho P, Dong Q, Bao B, Assinder S, McLennan S, Richardson D, Ammit A, Sharland A, Hardikar A, Hong A, Hambly B, Lee C, Murphy C, Goldsbury C, Johnstone D, Lane D, Hibbs D, Joshua D, Huq F, Halliday G, Sutherland G, Zreiqat H, Lok H, Lyons G, Jansson P, Black J, Zhu L, Sunde M, Day M, Naylor M, Buckland M, Murray M, Shafie N, Lay P, Poronnik P, Codd R, Mason R, Ryan R, Christopherson R, de Graaf S; National Health and Medical Research Council (NHMRC)/Equipment Grants.

2013

  • QX100 Droplet Digital PCR system for Shared Used at the Open Access, Multi-User Molecular Biology Core Facility; Richardson D, Kril J, Murphy C, Vandenberg R, Rendina L, Dos Remedios C, Ju Y, Kovacevic Z, Lyons G, Sutherland G, Lay P, Ammit A, Lai D, Morris B, Day M, Dong Q, Bao B, Huang M, Camp A, Boyer M, Whittington R, Byrne M, Hanrahan J, Fu D, Jansson P, Lane D, Bagley E, Hibbs D, Zhang D, Fraser S, Scolyer R, Black J, Halliday G, Christie M, Zreiqat H, Murray M, Slobedman B, Naylor M, Burgess J, Triccas J, Mason R, Chadban S, Combes V, Lovicu F, McLennan S, Kalinowski D, Sharland A, Johnstone D, Groundwater P, Dixon K, Zhou F, Lovejoy D, Lu Z, Zhu L, Goldsbury C, Witting P, Buckland M, Assinder S, Purdie (Williams) A, Codd R, Owens T, Hambly B; National Health and Medical Research Council (NHMRC)/Equipment Grants.
  • Robotic High Throughput Western Analysis for the Open Access, Multi-User Sydney Cancer Research Core Facility; Richardson D, Scolyer R, Boyer M, Halliday G, Damian D, Christopherson R, Joshua D, Kench J, Hong A, Murray M, Lee C, Kalinowski D, Naylor M, Lay P, Lyons G, Kovacevic Z, Mason R, Dixon K, Chan-Ling T, Hawkins C, Sunde M, Lovejoy D, Owens T, Rendina L, Jansson P, Dos Remedios C, Charles (nee Slaviero) K, Lane D, Witting P, Dong Q, Ammit A, Groundwater P, Assinder S, Bao B, Byrne S, Zhou F, Buckland M, Grewal T, Huq F, Lai D, Codd R, Zhang D, Fu D, de Graaf S, Huang M, Payne R, Slobedman B, Barrs V, Ho P, Williamson P, Murphy C; DVC Research/Equipment Grant.

2012

  • GeneAtlas Personal Microarray System; Richardson D, Scolyer R, Stocker R, Weninger W, Black J, Allen D, Murray M, Mason R, Twigg S, King N, Horvath L, Lovicu F, Lee C, Halliday G, Lovejoy D, Joshua D, Sharland A, Roufogalis B, Hambly B, Morris B, Bao B, Bishop A, Hibbs D, Lane D, Zhou F, Hanrahan J, Dixon K, Rendina L, Byrne M, Naylor M, Cole N, Jansson P, Dong Q, Codd R, Payne R, Assinder S, Chadban S, Fraser S, McLennan S, Suryo Rahmanto A, Lai D, Yu Y, Ju Y, Buckland M, Kovacevic Z, Saletta F, Zreiqat H, Kalinowski D, Groundwater P, Simes R, Zhang D, Boyer M, Murphy C; National Health and Medical Research Council (NHMRC)/Equipment Grants.

2011

  • PyroMark Q96 ID system; Richardson D, Stone J, Black J, King N, Mason R, Hunt N, Kril J, Murray M, Scolyer R, Halliday G, Vandenberg R, McMinn P, Chadban S, Byrne M, Ryan R, Dong Q, Lee C, Bishop A, Haass N, Fraser S, Hambly B, Sharland A, Kalinowski D, Assinder S, Yu Y, Bao B, Ju Y, Lovejoy D, Buckland M, Lane D, Dos Remedios C, Kovacevic Z, Sutherland G, Zhang D, Morris B, Suryo Rahmanto A, Murphy C; National Health and Medical Research Council (NHMRC)/Equipment Grants.
  • The small animal bioimager; Halliday G, Hambley T, Zreiqat H, Richardson D, Holst J, Rasko J, Byrne S, Dong Q, Hong A, Lyons G; National Health and Medical Research Council (NHMRC)/Equipment Grants.
  • Using PSA to Activate Anticancer Prodrugs in Prostate Cancer; Dong Q, Hambley T; Prostate Cancer Foundation of Australia/PCFA Research Program.

2010

  • Treatment of prostate cancerEfficacy with cPLA2 inhibitor; Dong Q; DVC Research/Bridging Support Grant.
  • Pharmacological Targeting via AKT, PTEN, and TGF-beta Pathway Integration using Novel Therapeutics; Richardson D, Assinder S, Dong Q; National Health and Medical Research Council (NHMRC)/Project Grants.

2009

  • Inverted Multiphoton Intravital Microscope; Weninger W, Gorrell M, Halliday G, Jones C, Fazekas de St Groth B, Richardson D, Clarke S, Gamble J, Bertolino P, Vadas M, Dong Q, Rasko J, Holst J, McCaughan G, Byrne S, Saunders B, Triccas J, Haass N; National Health and Medical Research Council (NHMRC)/Equipment Grants.
  • Core Resource Facility - application for 7-laser flow cytometer and high content bioimaging system to enhance capabilities and throughput for the NSW Advanced Cytometry Facility; King N, Vadas M, Campbell I, Grau G, Britton W, Fazekas de St Groth B, Richardson D, Halliday G, Christopherson R, Gamble J, Mason R, Rasko J, McCaughan G, Weninger W, Xia P, Gorrell M, Holst J, Pile A, Sword G, McArthur C, Dong Q, Haass N, Sharland A, Saunders B, Triccas J, Norris J, Bertolino P, Bowen D, Sze D; National Health and Medical Research Council (NHMRC)/Equipment Grants.
  • Multi-photon microscope for intravital imaging; Weninger W, Vadas M, Hogg P, Norris M, Fazekas de St Groth B, Haass N, Clarke S, Halliday G, Rasko J, Holst J, McCaughan G, Allen J, Gamble J, Dong Q, Byrne S, Richardson D; Cancer Institute New South Wales/Equipment Grant.

2008

  • Dako ACIS III Cellular Image Acquisition and Analysis System; Gorrell M, Grau G, Bishop A, Black J, Campbell I, McLennan S, Rodgers K, Seth D, Marsh D, Dong Q, Hambly B, Bao B, King N, Markham R, McDonald K, Hunt N; Australian Research Council (ARC)/Linkage Infrastructure, Equipment and Facilities (LIEF).
  • Dako ACIS 111 Cellular Image Acquisition and Analysis System; Hambly B, Bao B, Bishop A, Black J, Campbell I, Dong Q, Gorrell M, Grau G, Hunt N, King N, Markham R, Marsh D, McDonald K, McLennan S, Rodgers K, Seth D; Australian Research Council (ARC)/Linkage Infrastructure, Equipment and Facilities (LIEF).

2007

  • PHERAstar and POLARstar Optima multi-functional plate readers with robotic high throughput screening system for multi-disciplinary cancer research; Halliday G, Ho P, Conigrave A, Iland H, Lee C, Joshua D, Cook D, Richardson D, Reichardt J, Grau G, Lovejoy D, Hunt N, King N, Mason R, Murphy C, Sharland A, Assinder S, Dong Q, Bishop A; Cancer Institute New South Wales/Infrastructure Grant.

2006

  • University of Sydney - Cancer Research Fund; Dong Q; University of Sydney/Cancer Research Fund.

2005

  • The oncogenic action of secretory Phospholipase A2(sPLA2)in Prostate Cancer; Barr D, Sved P, Dong Q; Australasian Urology Pty Ltd/BLO Project.
  • FACS Aria for the University of Sydney Flow Cytometry Facility; King N, Pollard J, Rasko J, Lovicu F, Bishop A, Bertolino P, Briscoe H, Gillies M, Madigan M, McAvoy J, Murphy C, Balcar V, Armour C, Hughes M, Reeve V, Christopherson R, Halliday G, Christie M, Pollock C, McCaughan G, Gorrell M, Dong Q, Abendroth A, Menzies S, Barnetson R, Byrne S, Hunt N, Hambly B, Cook D, Mason R, Day M, Black J; University of Sydney/Equipment Grant.
  • Cancer Inst NSW Fell05-Dong; Dong Q; Cancer Institute New South Wales/Research Grant.
  • A therapeutic target for advanced prostate cancer; Barr D, Dong Q; Australasian Urology Pty Ltd/BLO Project.

2004

  • Function and regulation of inhibitor of DNA binding-1 in prostate cancer; Dong Q; Cure Cancer Australia Foundation/Research Support.
  • Oncogenic action and therapeutic potential of PLA2 in prostate cancer; Dong Q, Kieran S, Graham N, Russell N; Hlth & Medical Research Grants/Research Grant.

2002

  • The role of FHL1 and SPINK1 in androgen-independent prostate cancer; Dong Q; Cancer Council New South Wales/Research Project Grants.

Selected publications

Download citations: PDF RTF Endnote

Book Chapters

  • Hua, S., Xie, C., Yao, M., Dong, Q. (2014). Effect of Arachidonic Acid and its Producing Enzyme Phospholipase A2 alpha on Key Oncogenic Pathways in Prostate Cancer. In Jason M. OKeefe (Eds.), Arachidonic Acid: Sources, Biosynthesis and Health Effects, (pp. 135-164). New York: Nova Science Publishers, Inc.
  • Young, L., Dong, Q. (2010). Targeted Amplification of Mutant Strands for Efficient Site-Directed Mutagenesis and Mutant Screening. In Jeff Braman (Eds.), In Vitro Mutagenesis Protocols, (pp. 147-155). New York: Humana Press.

Journals

  • Yao, M., Rogers (MacDonald), L., Suchowerska, N., Choe, D., Al-Dabbas, M., Narula, R., Lyons, G., Sved, P., Li, Z., Dong, Q. (2018). Sensitization of prostate cancer to radiation therapy: Molecules and pathways to target. Radiotherapy and Oncology, 128(2), 283-300. [More Information]
  • Zheng, T., Que, Z., Jiao, L., Kang, Y., Gong, Y., Yao, J., Ma, C., Bi, L., Dong, Q., Zhao, X., et al (2017). Herbal formula YYJD inhibits tumor growth by inducing cell cycle arrest and senescence in lung cancer. Scientific Reports, 7(1), 1-9. [More Information]
  • Xi, Z., Yao, M., Li, Y., Xie, C., Holst, J., Liu, T., Cai, S., Lao, Y., Tan, H., Xu, H., Dong, Q. (2016). Guttiferone K impedes cell cycle re-entry of quiescent prostate cancer cells via stabilization of FBXW7 and subsequent c-MYC degradation. Cell Death and Disease, 7(6), 1-13. [More Information]
  • Shen, K., Xi, Z., Xie, J., Wang, H., Xie, C., Lee, C., Fahey, P., Dong, Q., Xu, H. (2016). Guttiferone K suppresses cell motility and metastasis of hepatocellular carcinoma by restoring aberrantly reduced profilin 1. Oncotarget, 7(35), 56650-56663. [More Information]
  • Meng, X., Xu, H., Yao, M., Dong, Q., Zhang, X. (2016). Implication of unfolded protein response and autophagy in the treatment of BRAF inhibitor resistant melanoma. Anti-Cancer Agents in Medicinal Chemistry, 16(3), 291-298. [More Information]
  • Hua, S., Vignarajan, S., Yao, M., Xie, C., Sved, P., Dong, Q. (2015). AKT and cytosolic phospholipase A2α form a positive loop in prostate cancer cells. Current Cancer Drug Targets, 15(9), 781-791.
  • Choi, J., Desai, R., Zheng, Y., Yao, M., Dong, Q., Watson, G., Handelsman, D., Simanainen, U. (2015). Androgen actions via androgen receptor promote PTEN inactivation induced uterine cancer. Endocrine-Related Cancer, 22(5), 687-701. [More Information]
  • Meng, X., Yao, M., Zhang, X., Xu, H., Dong, Q. (2015). ER stress-induced autophagy in melanoma. Clinical and Experimental Pharmacology and Physiology, 42(8), 811-816. [More Information]
  • Hnit, S., Xie, C., Yao, M., Holst, J., Bensoussan, A., de Souza, P., Li, Z., Dong, Q. (2015). p27(Kip1) signaling: Transcriptional and post-translational regulation. The International Journal of Biochemistry and Cell Biology, 68, 9-14. [More Information]
  • Yao, M., Xie, C., Kiang, M., Teng, Y., Harman, D., Tiffen, J., Wang, K., Sved, P., Bao, B., Witting, P., Holst, J., Dong, Q. (2015). Targeting of cytosolic phospholipase A2a impedes cell cycle re-entry of quiescent prostate cancer cells. Oncotarget, 6(33), 34458-34474. [More Information]
  • Gamsjaeger, R., Kariawasam, R., Gimenez, A., Touma, C., McIlwain, E., Bernardo, R., Shepherd, N., Ataide, S., Dong, Q., Richard, D., Cubeddu, L., et al (2015). The structural basis of DNA binding by the single-stranded DNA-binding protein from Sulfolobus solfataricus. The Biochemical Journal, 465(2), 337-346. [More Information]
  • Vignarajan, S., Xie, C., Yao, M., Sun, Y., Simanainen, U., Sved, P., Liu, T., Dong, Q. (2014). Loss of PTEN stabilizes the lipid modifying enzyme cytosolic phospholipase A2a via AKT in prostate cancer cells. Oncotarget, 5(15), 6289-6299. [More Information]
  • Xie, C., Yao, M., Dong, Q. (2014). Proliferating cell unclear antigen-associated factor (PAF15): A novel oncogene. The International Journal of Biochemistry and Cell Biology, 50(1), 127-131. [More Information]
  • Zheng, Z., He, X., Xie, C., Hua, S., Li, J., Wang, T., Yao, M., Vignarajan, S., Teng, Y., Hejazi, L., Dong, Q., et al (2014). Targeting cytosolic phospholipase A2alpha in colorectal cancer cells inhibits constitutively activated Protein Kinase B (AKT) and cell proliferation. Oncotarget, 5(23), 12304-12316. [More Information]
  • Xie, C., Powell, C., Yao, M., Wu, J., Dong, Q. (2014). Ubiquitin-conjugating enzyme E2C: A potential cancer biomarker. The International Journal of Biochemistry and Cell Biology, 47, 113-117. [More Information]
  • Xiao, W., Graham, P., Hao, J., Chang, L., Ni, J., Power, C., Dong, Q., Kearsley, J., Li, Y. (2013). Combination Therapy with the Histone Deacetylase Inhibitor LBH589 and Radiation Is an Effective Regimen for Prostate Cancer Cells. PloS One, 8(8), 1-14. [More Information]
  • Hua, S., Yao, M., Vignarajan, S., Witting, P., Hejazi, L., Gong, Z., Teng, Y., Niknami, M., Assinder, S., Richardson, D., Dong, Q. (2013). Cytosolic phospholipase A2alpha sustains pAKT, pERK and AR levels in PTEN-null/mutated prostate cancer cells. Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids, 1831 (6), 1146-1157. [More Information]
  • Dixon, K., Lui, G., Kovacevic, Z., Zhang, D., Yao, M., Chen, Z., Dong, Q., Assinder, S., Richardson, D. (2013). Dp44mT targets the AKT, TGF-β and ERK pathways via the metastasis suppressor NDRG1 in normal prostate epithelial cells and prostate cancer cells. British Journal of Cancer, 108(2), 409-419. [More Information]
  • Ghalayini, M., Dong, Q., Richardson, D., Assinder, S. (2013). Proteolytic cleavage and truncation of NDRG1 in human prostate cancer cells, but not normal prostate epithelial cells. Bioscience Reports, 33(3), 451-464. [More Information]
  • Garbutcheon-Singh, B., Myers, S., Harper, B., Ng, N., Dong, Q., Xie, C., Aldrich-Wright, J. (2013). The effects of 56MESS on mitochondrial and cytoskeletal proteins and the cell cycle in MDCK cells. Metallomics, 5(8), 1061-1067. [More Information]
  • Yao, M., Xie, C., Constantine, M., Hua, S., Hambly, B., Jardine, G., Sved, P., Dong, Q. (2012). How can food extracts consumed in the Mediterranean and East Asia suppress prostate cancer proliferation? British Journal of Nutrition, 108(3), 424-430. [More Information]
  • Assinder, S., Au, E., Dong, Q., Winnick, C. (2010). A novel splice variant of the beta-tropomyosin (TPM2) gene in prostate cancer. Molecular Carcinogenesis, 49(6), 525-531. [More Information]
  • Niknami, M., Vignarajan, S., Yao, M., Hua, S., Witting, P., Kita, Y., Shimizu, T., Sved, P., Patel, M., Dong, Q. (2010). Decrease in expression or activity of cytosolic phospholipase A(2)alpha increases cyclooxygenase-1 action: A cross-talk between key enzymes in arachidonic acid pathway in prostate cancer cells. Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids, 1801 (7), 731-737. [More Information]
  • Singh, J., Xie, C., Yao, M., Hua, S., Vignarajan, S., Jardine, G., Hambly, B., Sved, P., Dong, Q. (2010). Food Extracts Consumed in Mediterranean Countries and East Asia Reduce Protein Concentrations of Androgen Receptor, Phospho-Protein Kinase B, and Phospho-Cytosolic Phospholipase A2α in Human Prostate Cancer Cells. The Journal of Nutrition, 140(4), 786-791. [More Information]
  • Yao, M., Taylor, R., Richards, M., Sved, P., Wong, J., Eisinger, D., Xie, C., Salomon, R., Risbridger, G., Dong, Q. (2010). Prostate-Regenerating Capacity of Cultured Human Adult Prostate Epithelial Cells. Cells Tissues Organs, 191(3), 203-212. [More Information]
  • Niknami, M., Patel, M., Witting, P., Dong, Q. (2009). Molecules in focus: Cytosolic phospholipase A(2)-{alpha}. The International Journal of Biochemistry and Cell Biology, 41(5), 994-997. [More Information]
  • Assinder, S., Dong, Q., Mangs, A., Richardson, D. (2009). Pharmacological targeting of the integrated protein kinase B, phosphatase and tensin homolog deleted on chromosome 10, and transforming growth Factor-β pathways in prostate cancer. Molecular Pharmacology, 75(3), 429-436. [More Information]
  • Niknami, M., Dong, Q., Witting, P. (2009). Pitfalls in the use of arachidonic acid oxidation products to assign lipoxygenase activity in cancer cells. Free Radical Research, 43(10), 951-956. [More Information]
  • Salomon, R., Young, L., Macleod, D., Yu, X., Dong, Q. (2009). Probasin Promoter-driven Expression of ID1 Is not Sufficient for Carcinogenesis in Rodent Prostate. Journal of Histochemistry and Cytochemistry: imaging the spectrum of cell biology, 57(6), 599-604. [More Information]
  • Richards, A., McGeechan, K., Niknami, M., Salomon, R., Kurek, C., Dong, Q., Patel, M. (2009). Prolonging androgen sensitivity in prostate cancer - a role for COX inhibitors? ANZ Journal of Surgery, 79(9), 641-647. [More Information]
  • Assinder, S., Dong, Q., Kovacevic, Z., Richardson, D. (2009). The TGF-beta, PI3K/Akt and PTEN pathways: established and proposed biochemical integration in prostate cancer. Biochemical Journal, 417(2), 411-421. [More Information]
  • Niknami, M., Patel, M., Witting, P., Dong, Q. (2008). Aberrant Activation of Arachidonic Acid and Eicosanoid Pathways- Targets for Treating Prostate Cancer. Recent Patents on Endocrine, Metabolic and Immune Drug Discovery, 2(1), 9-15. [More Information]
  • Patel, M., Singh, J., Niknami, M., Kurek, C., Yao, M., Lu, S., Maclean, F., King, N., Gelb, M., Scott, K., Dong, Q., et al (2008). Cytosolic PhospholipaseA2-A: A Potential Therapeutic Target for Prostate Cancer. Clinical Cancer Research, 14(24), 8070-8079. [More Information]
  • Patel, M., Kurek, C., Dong, Q. (2008). The Arachidonic Acid Pathway and its Role in Prostate Cancer Development and Progression. The Journal of Urology, 179(5), 1668-1675. [More Information]
  • Dong, Q., Patel, M., Scott, K., Graham, G., Russell, P., Sved, P. (2006). Oncogenic action of phospholipase A(2) in prostate cancer. Cancer Letters, 240(1), 9-16. [More Information]
  • Young, L., Salomon, R., Au, W., Allan, C., Russell, P., Dong, Q. (2006). Ornithine decarboxylase (ODC) expression pattern in human prostate tissues and ODC transgenic mice. Journal of Histochemistry and Cytochemistry: imaging the spectrum of cell biology, 54(2), 223-229. [More Information]
  • Lim, W., Tan, B., Zhu, Y., Zhou, S., Armstrong, J., Li, Q., Dong, Q., Chan, E., Smith, D., Verma, C., et al (2006). The very C-terminus of PRK1/PKN is essential for its activation by RhoA and downstream signaling. Cellular Signalling, 18(9), 1473-1481. [More Information]
  • Patel, M., Tuckermann, R., Dong, Q. (2005). A Pitfall of the 3-(4,5-dimethylthiazol-2-yl)-5(3-carboxymethonyphenol)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay due to evaporation in wells on the edge of a 96 well plate. Biotechnology Letters, 27(11), 805-808. [More Information]
  • Singh, J., Manickam, P., Shmoish, M., Natik, S., Denyer, G., Handelsman, D., Gong, D., Dong, Q. (2005). Annotation of androgen dependence to human prostate cancer-associated genes by microarray analysis of mouse prostate. Cancer Letters, 237(2), 298-304. [More Information]
  • Dong, Q., Young, L. (2005). Development of a murine prostatespecific 2-in-1 inducible bicistronic expression vector. Biotechnology Letters, 27(12), 823-8. [More Information]
  • Singh, J., Young, L., Handelsman, D., Dong, Q. (2005). Molecular cloning and characterization of a novel androgen repressible gene expressed in the prostate epithelium. Gene, 348(1), 55-63. [More Information]
  • Dong, Q., Patel, M., Scott, K., Graham, G., Russell, P., Sved, P. (2005). Oncogenic action of phospholipase A(2) in prostate cancer. Cancer Letters, 240(1), 9-16. [More Information]
  • Zhu, Y., Dong, Q., Tan, B., Lim, W., Zhou, S., Duan, W. (2005). The PKC alpha-D294G mutant found in pituitary and thyroid tumors fails to transduce extracellular signals. Cancer Research, 65(11), 4520-4524. [More Information]
  • Sved, P., Scott, K., McLeod, D., King, N., Singh, J., Tsatralis, T., Nikolov, B., Boulas, J., Nallan, L., Gelb, M., Dong, Q., et al (2004). Oncogenic Action Of Secreted Phospholipase A2 In Prostate Cancer. Cancer Research, 64(19), 6934-6940. [More Information]
  • Young, L., Dong, Q. (2004). Two-Step Total Gene Synthesis Method. Nucleic Acids Research, 32(7), e59.
  • Young, L., Dong, Q. (2003). TAMS technology for simple and efficient in vitro site-directed mutagenesis and mutant screening. Nucleic Acids Research, 31(3/e11), 1-3.
  • Singh, J., Young, L., Handelsman, D., Dong, Q. (2002). Prostate epithelial expression of a novel androgen target gene. Journal Of Andrology, 23(5), 652-660.
  • Chetcuti, A., Margan, S., Russell, P., Handelsman, D., Dong, Q., Mann, S., Rogers, J. (2001). Identification of differentially expressed genes in organ-confined prostate cancer by gene expression array. The Prostate, 47, 132-140.
  • Chetcuti, A., Margan, S., Russell, P., Mann, S., Millar,, D., Clark, S., Rogers, J., Handelsman, D., Dong, Q. (2001). Loss of annexin II heavy and light chains in prostate cancer and its precursors. Cancer Research, 61, 6331-6334.
  • Foxley, G., Dong, Q., Handelsman, D. (2001). Quantitative reverse transcriptase polymerase chain reaction assay for mouse androgen receptor mRNA. Endocrine, 15, 193-198.
  • Chua, E., Wu, W., Tran, K., McCarthy, S., Lauer, C., Dubourdieu, D., Packham, N., O'Brien, C., Turtle, J., Dong, Q. (2000). Prevalence and Distribution of ret/ptc 1, 2, and 3 in Papillary Thyroid Carcinoma in New Caledonia and Australia. The Journal of Clinical Endocrinology and Metabolism, 85, 2733-2739.

2018

  • Yao, M., Rogers (MacDonald), L., Suchowerska, N., Choe, D., Al-Dabbas, M., Narula, R., Lyons, G., Sved, P., Li, Z., Dong, Q. (2018). Sensitization of prostate cancer to radiation therapy: Molecules and pathways to target. Radiotherapy and Oncology, 128(2), 283-300. [More Information]

2017

  • Zheng, T., Que, Z., Jiao, L., Kang, Y., Gong, Y., Yao, J., Ma, C., Bi, L., Dong, Q., Zhao, X., et al (2017). Herbal formula YYJD inhibits tumor growth by inducing cell cycle arrest and senescence in lung cancer. Scientific Reports, 7(1), 1-9. [More Information]

2016

  • Xi, Z., Yao, M., Li, Y., Xie, C., Holst, J., Liu, T., Cai, S., Lao, Y., Tan, H., Xu, H., Dong, Q. (2016). Guttiferone K impedes cell cycle re-entry of quiescent prostate cancer cells via stabilization of FBXW7 and subsequent c-MYC degradation. Cell Death and Disease, 7(6), 1-13. [More Information]
  • Shen, K., Xi, Z., Xie, J., Wang, H., Xie, C., Lee, C., Fahey, P., Dong, Q., Xu, H. (2016). Guttiferone K suppresses cell motility and metastasis of hepatocellular carcinoma by restoring aberrantly reduced profilin 1. Oncotarget, 7(35), 56650-56663. [More Information]
  • Meng, X., Xu, H., Yao, M., Dong, Q., Zhang, X. (2016). Implication of unfolded protein response and autophagy in the treatment of BRAF inhibitor resistant melanoma. Anti-Cancer Agents in Medicinal Chemistry, 16(3), 291-298. [More Information]

2015

  • Hua, S., Vignarajan, S., Yao, M., Xie, C., Sved, P., Dong, Q. (2015). AKT and cytosolic phospholipase A2α form a positive loop in prostate cancer cells. Current Cancer Drug Targets, 15(9), 781-791.
  • Choi, J., Desai, R., Zheng, Y., Yao, M., Dong, Q., Watson, G., Handelsman, D., Simanainen, U. (2015). Androgen actions via androgen receptor promote PTEN inactivation induced uterine cancer. Endocrine-Related Cancer, 22(5), 687-701. [More Information]
  • Meng, X., Yao, M., Zhang, X., Xu, H., Dong, Q. (2015). ER stress-induced autophagy in melanoma. Clinical and Experimental Pharmacology and Physiology, 42(8), 811-816. [More Information]
  • Hnit, S., Xie, C., Yao, M., Holst, J., Bensoussan, A., de Souza, P., Li, Z., Dong, Q. (2015). p27(Kip1) signaling: Transcriptional and post-translational regulation. The International Journal of Biochemistry and Cell Biology, 68, 9-14. [More Information]
  • Yao, M., Xie, C., Kiang, M., Teng, Y., Harman, D., Tiffen, J., Wang, K., Sved, P., Bao, B., Witting, P., Holst, J., Dong, Q. (2015). Targeting of cytosolic phospholipase A2a impedes cell cycle re-entry of quiescent prostate cancer cells. Oncotarget, 6(33), 34458-34474. [More Information]
  • Gamsjaeger, R., Kariawasam, R., Gimenez, A., Touma, C., McIlwain, E., Bernardo, R., Shepherd, N., Ataide, S., Dong, Q., Richard, D., Cubeddu, L., et al (2015). The structural basis of DNA binding by the single-stranded DNA-binding protein from Sulfolobus solfataricus. The Biochemical Journal, 465(2), 337-346. [More Information]

2014

  • Hua, S., Xie, C., Yao, M., Dong, Q. (2014). Effect of Arachidonic Acid and its Producing Enzyme Phospholipase A2 alpha on Key Oncogenic Pathways in Prostate Cancer. In Jason M. OKeefe (Eds.), Arachidonic Acid: Sources, Biosynthesis and Health Effects, (pp. 135-164). New York: Nova Science Publishers, Inc.
  • Vignarajan, S., Xie, C., Yao, M., Sun, Y., Simanainen, U., Sved, P., Liu, T., Dong, Q. (2014). Loss of PTEN stabilizes the lipid modifying enzyme cytosolic phospholipase A2a via AKT in prostate cancer cells. Oncotarget, 5(15), 6289-6299. [More Information]
  • Xie, C., Yao, M., Dong, Q. (2014). Proliferating cell unclear antigen-associated factor (PAF15): A novel oncogene. The International Journal of Biochemistry and Cell Biology, 50(1), 127-131. [More Information]
  • Zheng, Z., He, X., Xie, C., Hua, S., Li, J., Wang, T., Yao, M., Vignarajan, S., Teng, Y., Hejazi, L., Dong, Q., et al (2014). Targeting cytosolic phospholipase A2alpha in colorectal cancer cells inhibits constitutively activated Protein Kinase B (AKT) and cell proliferation. Oncotarget, 5(23), 12304-12316. [More Information]
  • Xie, C., Powell, C., Yao, M., Wu, J., Dong, Q. (2014). Ubiquitin-conjugating enzyme E2C: A potential cancer biomarker. The International Journal of Biochemistry and Cell Biology, 47, 113-117. [More Information]

2013

  • Xiao, W., Graham, P., Hao, J., Chang, L., Ni, J., Power, C., Dong, Q., Kearsley, J., Li, Y. (2013). Combination Therapy with the Histone Deacetylase Inhibitor LBH589 and Radiation Is an Effective Regimen for Prostate Cancer Cells. PloS One, 8(8), 1-14. [More Information]
  • Hua, S., Yao, M., Vignarajan, S., Witting, P., Hejazi, L., Gong, Z., Teng, Y., Niknami, M., Assinder, S., Richardson, D., Dong, Q. (2013). Cytosolic phospholipase A2alpha sustains pAKT, pERK and AR levels in PTEN-null/mutated prostate cancer cells. Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids, 1831 (6), 1146-1157. [More Information]
  • Dixon, K., Lui, G., Kovacevic, Z., Zhang, D., Yao, M., Chen, Z., Dong, Q., Assinder, S., Richardson, D. (2013). Dp44mT targets the AKT, TGF-β and ERK pathways via the metastasis suppressor NDRG1 in normal prostate epithelial cells and prostate cancer cells. British Journal of Cancer, 108(2), 409-419. [More Information]
  • Ghalayini, M., Dong, Q., Richardson, D., Assinder, S. (2013). Proteolytic cleavage and truncation of NDRG1 in human prostate cancer cells, but not normal prostate epithelial cells. Bioscience Reports, 33(3), 451-464. [More Information]
  • Garbutcheon-Singh, B., Myers, S., Harper, B., Ng, N., Dong, Q., Xie, C., Aldrich-Wright, J. (2013). The effects of 56MESS on mitochondrial and cytoskeletal proteins and the cell cycle in MDCK cells. Metallomics, 5(8), 1061-1067. [More Information]

2012

  • Yao, M., Xie, C., Constantine, M., Hua, S., Hambly, B., Jardine, G., Sved, P., Dong, Q. (2012). How can food extracts consumed in the Mediterranean and East Asia suppress prostate cancer proliferation? British Journal of Nutrition, 108(3), 424-430. [More Information]

2010

  • Assinder, S., Au, E., Dong, Q., Winnick, C. (2010). A novel splice variant of the beta-tropomyosin (TPM2) gene in prostate cancer. Molecular Carcinogenesis, 49(6), 525-531. [More Information]
  • Niknami, M., Vignarajan, S., Yao, M., Hua, S., Witting, P., Kita, Y., Shimizu, T., Sved, P., Patel, M., Dong, Q. (2010). Decrease in expression or activity of cytosolic phospholipase A(2)alpha increases cyclooxygenase-1 action: A cross-talk between key enzymes in arachidonic acid pathway in prostate cancer cells. Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids, 1801 (7), 731-737. [More Information]
  • Singh, J., Xie, C., Yao, M., Hua, S., Vignarajan, S., Jardine, G., Hambly, B., Sved, P., Dong, Q. (2010). Food Extracts Consumed in Mediterranean Countries and East Asia Reduce Protein Concentrations of Androgen Receptor, Phospho-Protein Kinase B, and Phospho-Cytosolic Phospholipase A2α in Human Prostate Cancer Cells. The Journal of Nutrition, 140(4), 786-791. [More Information]
  • Yao, M., Taylor, R., Richards, M., Sved, P., Wong, J., Eisinger, D., Xie, C., Salomon, R., Risbridger, G., Dong, Q. (2010). Prostate-Regenerating Capacity of Cultured Human Adult Prostate Epithelial Cells. Cells Tissues Organs, 191(3), 203-212. [More Information]
  • Young, L., Dong, Q. (2010). Targeted Amplification of Mutant Strands for Efficient Site-Directed Mutagenesis and Mutant Screening. In Jeff Braman (Eds.), In Vitro Mutagenesis Protocols, (pp. 147-155). New York: Humana Press.

2009

  • Niknami, M., Patel, M., Witting, P., Dong, Q. (2009). Molecules in focus: Cytosolic phospholipase A(2)-{alpha}. The International Journal of Biochemistry and Cell Biology, 41(5), 994-997. [More Information]
  • Assinder, S., Dong, Q., Mangs, A., Richardson, D. (2009). Pharmacological targeting of the integrated protein kinase B, phosphatase and tensin homolog deleted on chromosome 10, and transforming growth Factor-β pathways in prostate cancer. Molecular Pharmacology, 75(3), 429-436. [More Information]
  • Niknami, M., Dong, Q., Witting, P. (2009). Pitfalls in the use of arachidonic acid oxidation products to assign lipoxygenase activity in cancer cells. Free Radical Research, 43(10), 951-956. [More Information]
  • Salomon, R., Young, L., Macleod, D., Yu, X., Dong, Q. (2009). Probasin Promoter-driven Expression of ID1 Is not Sufficient for Carcinogenesis in Rodent Prostate. Journal of Histochemistry and Cytochemistry: imaging the spectrum of cell biology, 57(6), 599-604. [More Information]
  • Richards, A., McGeechan, K., Niknami, M., Salomon, R., Kurek, C., Dong, Q., Patel, M. (2009). Prolonging androgen sensitivity in prostate cancer - a role for COX inhibitors? ANZ Journal of Surgery, 79(9), 641-647. [More Information]
  • Assinder, S., Dong, Q., Kovacevic, Z., Richardson, D. (2009). The TGF-beta, PI3K/Akt and PTEN pathways: established and proposed biochemical integration in prostate cancer. Biochemical Journal, 417(2), 411-421. [More Information]

2008

  • Niknami, M., Patel, M., Witting, P., Dong, Q. (2008). Aberrant Activation of Arachidonic Acid and Eicosanoid Pathways- Targets for Treating Prostate Cancer. Recent Patents on Endocrine, Metabolic and Immune Drug Discovery, 2(1), 9-15. [More Information]
  • Patel, M., Singh, J., Niknami, M., Kurek, C., Yao, M., Lu, S., Maclean, F., King, N., Gelb, M., Scott, K., Dong, Q., et al (2008). Cytosolic PhospholipaseA2-A: A Potential Therapeutic Target for Prostate Cancer. Clinical Cancer Research, 14(24), 8070-8079. [More Information]
  • Patel, M., Kurek, C., Dong, Q. (2008). The Arachidonic Acid Pathway and its Role in Prostate Cancer Development and Progression. The Journal of Urology, 179(5), 1668-1675. [More Information]

2006

  • Dong, Q., Patel, M., Scott, K., Graham, G., Russell, P., Sved, P. (2006). Oncogenic action of phospholipase A(2) in prostate cancer. Cancer Letters, 240(1), 9-16. [More Information]
  • Young, L., Salomon, R., Au, W., Allan, C., Russell, P., Dong, Q. (2006). Ornithine decarboxylase (ODC) expression pattern in human prostate tissues and ODC transgenic mice. Journal of Histochemistry and Cytochemistry: imaging the spectrum of cell biology, 54(2), 223-229. [More Information]
  • Lim, W., Tan, B., Zhu, Y., Zhou, S., Armstrong, J., Li, Q., Dong, Q., Chan, E., Smith, D., Verma, C., et al (2006). The very C-terminus of PRK1/PKN is essential for its activation by RhoA and downstream signaling. Cellular Signalling, 18(9), 1473-1481. [More Information]

2005

  • Patel, M., Tuckermann, R., Dong, Q. (2005). A Pitfall of the 3-(4,5-dimethylthiazol-2-yl)-5(3-carboxymethonyphenol)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay due to evaporation in wells on the edge of a 96 well plate. Biotechnology Letters, 27(11), 805-808. [More Information]
  • Singh, J., Manickam, P., Shmoish, M., Natik, S., Denyer, G., Handelsman, D., Gong, D., Dong, Q. (2005). Annotation of androgen dependence to human prostate cancer-associated genes by microarray analysis of mouse prostate. Cancer Letters, 237(2), 298-304. [More Information]
  • Dong, Q., Young, L. (2005). Development of a murine prostatespecific 2-in-1 inducible bicistronic expression vector. Biotechnology Letters, 27(12), 823-8. [More Information]
  • Singh, J., Young, L., Handelsman, D., Dong, Q. (2005). Molecular cloning and characterization of a novel androgen repressible gene expressed in the prostate epithelium. Gene, 348(1), 55-63. [More Information]
  • Dong, Q., Patel, M., Scott, K., Graham, G., Russell, P., Sved, P. (2005). Oncogenic action of phospholipase A(2) in prostate cancer. Cancer Letters, 240(1), 9-16. [More Information]
  • Zhu, Y., Dong, Q., Tan, B., Lim, W., Zhou, S., Duan, W. (2005). The PKC alpha-D294G mutant found in pituitary and thyroid tumors fails to transduce extracellular signals. Cancer Research, 65(11), 4520-4524. [More Information]

2004

  • Sved, P., Scott, K., McLeod, D., King, N., Singh, J., Tsatralis, T., Nikolov, B., Boulas, J., Nallan, L., Gelb, M., Dong, Q., et al (2004). Oncogenic Action Of Secreted Phospholipase A2 In Prostate Cancer. Cancer Research, 64(19), 6934-6940. [More Information]
  • Young, L., Dong, Q. (2004). Two-Step Total Gene Synthesis Method. Nucleic Acids Research, 32(7), e59.

2003

  • Young, L., Dong, Q. (2003). TAMS technology for simple and efficient in vitro site-directed mutagenesis and mutant screening. Nucleic Acids Research, 31(3/e11), 1-3.

2002

  • Singh, J., Young, L., Handelsman, D., Dong, Q. (2002). Prostate epithelial expression of a novel androgen target gene. Journal Of Andrology, 23(5), 652-660.

2001

  • Chetcuti, A., Margan, S., Russell, P., Handelsman, D., Dong, Q., Mann, S., Rogers, J. (2001). Identification of differentially expressed genes in organ-confined prostate cancer by gene expression array. The Prostate, 47, 132-140.
  • Chetcuti, A., Margan, S., Russell, P., Mann, S., Millar,, D., Clark, S., Rogers, J., Handelsman, D., Dong, Q. (2001). Loss of annexin II heavy and light chains in prostate cancer and its precursors. Cancer Research, 61, 6331-6334.
  • Foxley, G., Dong, Q., Handelsman, D. (2001). Quantitative reverse transcriptase polymerase chain reaction assay for mouse androgen receptor mRNA. Endocrine, 15, 193-198.

2000

  • Chua, E., Wu, W., Tran, K., McCarthy, S., Lauer, C., Dubourdieu, D., Packham, N., O'Brien, C., Turtle, J., Dong, Q. (2000). Prevalence and Distribution of ret/ptc 1, 2, and 3 in Papillary Thyroid Carcinoma in New Caledonia and Australia. The Journal of Clinical Endocrinology and Metabolism, 85, 2733-2739.

To update your profile click here. For support on your academic profile contact .